We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Diabetes Drug Prevents Alzheimer's Disease in Mouse Model

By LabMedica International staff writers
Posted on 06 Dec 2010
The biguanide drug metformin, which is used to treat type II diabetes, has been found to block phosphorylation of the tau proteins that are present in insoluble tangles in the brains of Alzheimer's disease patients.

Hyperphosphorylation of the tau protein can result in the self-assembly of tangles of paired helical filaments and straight filaments, which are involved in the pathogenesis of Alzheimer's disease and other tauopathies. More...
When misfolded, this otherwise very soluble protein can form extremely insoluble aggregates that contribute to a number of neurodegenerative diseases.

Investigators at the German Center for Neurodegenerative Diseases (Munich) and their colleagues at the University of Dundee (United Kingdom) and the Max-Planck-Institute for Molecular Genetics (Berlin, Germany) were seeking drugs that would block phosphorylation of tau proteins and prevent the destruction of brain neurons.

In the current study they focused on the diabetes drug metformin, which was known to activate the enzyme protein phosphatase 2A (PP2A), the major tau phosphatase. Activation of PP2A would be expected to reverse tau hyperphosphorylation.

The investigators worked with both cell cultures - primary neurons taken from wild type and human tau transgenic mice - and in vivo with the two different lines of mice. They reported in the November 22, 2010, online edition of the journal Proceedings of the [US] National Academy of Sciences (PNAS) that metformin induced PP2A activity and reduced tau phosphorylation at PP2A-dependent epitopes in vitro and in vivo. This tau dephosphorylating potency could be blocked entirely by the PP2A inhibitors okadaic acid and fostriecin, confirming that PP2A was an important mediator of the observed effects. Affinity chromatography and immunoprecipitation experiments together with PP2A activity assays indicated that metformin interfered with the binding properties of the catalytic subunit of PP2A and thereby influenced PP2A activity.

"So far there is no drug on the market that targets the formation of tau aggregates,” said contributing author Dr. Sybille Krauss, a researcher at the German Center for Neurodegenerative Diseases. "If we can confirm that metformin shows also an effect in humans, it is certainly a good candidate for an effective therapy on Alzheimer's diseases.”

Related Links:

German Center for Neurodegenerative Diseases
University of Dundee
Max-Planck-Institute for Molecular Genetics




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HPV Test
Allplex HPV28 Detection
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.